Zomedica Corp.

Zomedica Corp. announced record second-quarter revenue of $9.5 million for Q2 2026, marking a 37% increase year-over-year and extending its streak of consecutive year-over-year revenue growth to 22 quarters. The company significantly reduced its net loss by 49% to $3.8 million and improved cash burn by 38% to $3.4 million, its lowest non-year-end quarterly cash burn on record. Growth was driven by strong performance in its Diagnostics and Therapeutic Devices segments, alongside contributions from the newly formed Development Services segment, while maintaining $44.1 million in liquidity.

Zomedica Corp. reported a substantial increase in net revenue for the second quarter and first half of 2026, driven by strong growth across its Diagnostics and Therapeutic Devices segments, and the emergence of Development Services revenue. The company also significantly reduced its net loss compared to the prior year, primarily due to the absence of a large impairment charge recorded in 2025. Despite the revenue growth, cash and total assets decreased from year-end 2025.

Zomedica Corp. held its Annual Meeting of Shareholders on June 10, 2026, where shareholders elected all eight director nominees and ratified the appointment of Grant Thornton LLP as its independent auditor. An amendment to the company's By-Laws concerning quorum requirements for adjourned meetings was also approved. However, shareholders did not approve, on an advisory basis, the compensation of the company's named executive officers.

Zomedica Corp. announced record first-quarter revenue of $8.8 million for Q1 2026, reflecting 35% annual growth and marking the 21st consecutive quarter of year-over-year revenue increase. Performance was driven by strong sales of therapeutic devices, continued adoption of diagnostic offerings like TRUFORMA®, and contributions from the newly formed Development Services segment, which generated $2.0 million. The company also reported a 21% reduction in adjusted operating expenses and a 15% decrease in cash burn, while maintaining $47.5 million in liquidity.

Zomedica Corp. reported a significant improvement in its financial performance for the first quarter ended March 31, 2026, with net loss narrowing to $(4.53) million from $(63.81) million in the prior year, largely due to the absence of a substantial impairment charge. Total net revenue increased by 35.4% to $8.80 million, driven by strong growth in Diagnostics and the new Development Services segment. The company also saw reduced operating expenses across general and administrative, research and development, and selling and marketing categories.

Zomedica Corp. filed a definitive proxy statement (DEF 14A) for its Annual Meeting of Shareholders to be held virtually on June 10, 2026. Shareholders will vote on the election of eight director nominees, the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2026, an advisory vote on executive compensation, and an amendment to the Company's By-Laws concerning quorum requirements for adjourned meetings. The record date for shareholders entitled to vote is April 21, 2026.